July 2022

BA.2.12.1, BA.4, and BA.5 escape antibodies elicited by Omicron infection

SARS-CoV-2 Omicron sublineages BA.2.12.1, BA.4 and BA.5 exhibit higher transmissibility over BA.21. The new variants’ receptor binding and immune evasion capability require immediate investigation. Here, coupled with Spike structural comparisons, we show that BA.2.12.1 and BA.4/BA.5 exhibit comparable ACE2-binding affinities to BA.2. Importantly, BA.2.12.1 and BA.4/BA.5 display stronger neutralization evasion than BA.2 against the plasma […]

BA.2.12.1, BA.4, and BA.5 escape antibodies elicited by Omicron infection Read More »

Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States

Summary – What is already known about this topic? SARS-CoV-2 infection is associated with worsening of diabetes symptoms, and persons with diabetes are at increased risk for severe COVID-19. SARS-CoV-2 infection might also induce newly diagnosed diabetes. What is added by this report? Persons aged <18 years with COVID-19 were more likely to receive a

Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States Read More »

New COVID-19 Vaccine Effectiveness Data Showcase Protection Gained by 3rd and 4th Doses

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can

New COVID-19 Vaccine Effectiveness Data Showcase Protection Gained by 3rd and 4th Doses Read More »

css.php
Scroll to Top